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1 Abbreviations 
αSMA- alpha-smooth muscle actin, Ang-2- angiopoietin-2, BRB- blood-retinal-barrier, Cx43- connexin-43, DAPI- 4′,6-
diamidino-2-phenylindole, DR- diabetic retinopathy, EC- endothelial cell, ECM- extracellular matrix, F-actin- filamentous 
actin , FBS- foetal bovine serum, GJ- gap junctions, hHGF- human hepatocyte growth factor, H- hour, hREC- human 
retinal microvascular endothelial cell, hRP- human retinal pericyte , IF- immunofluorescence, IL-8- interleukin-8, PET- 
polyethylene terephthalate, PDGF- platelet-derived growth factor, REC- retinal endothelial cell, RP- retinal pericyte, RT- 
room temperature, SD- standard deviation TC- tissue culture, TJ- tight junction, TIMP-2- tissue inhibitor for 






This human primary co-culture model using human retinal microvascular endothelial cells (hREC) 
and human retinal pericyte cells (hRP) aims to improve current understanding of the cellular 
changes occurring in the retinal microvasculature during diabetic retinopathy (DR). Currently, 
patients often present in clinic with late-stage DR, only when vision becomes impaired. Therefore, 
new strategies for earlier detection in clinic, combined with novel pharmaceutical and cellular 
interventions are essential in order to slow or halt the progression of DR from background to sight-
threatening stage. This co-culture model can be used as a simple, replicable in vitro tool to 
discover and assess novel drug therapies and improve fundamental understanding of alterations to 
cell behaviour in the human retinal microvasculature during DR. 
hRP and hREC were cultured for up to 21 days in normoxic (20%) or hypoxic (2%) oxygen levels 
and physiological (5.5mM) or very high (33mM) glucose, to maintain a healthy, or induce a 
diabetic-like phenotype in vitro. Mono- or co-cultured hREC and hRP were seeded 1:1 in healthy 
(20% oxygen and 5.5mM glucose) or diabetic-like (2% oxygen and 33mM glucose) conditions, on 
either side of untreated polyethylene terephthalate (PET) transwell inserts, and cultured for 21 
days. Mono- and co-cultures were analysed for changes in metabolic activity, angiogenic response 
and junctional protein expression, using immunofluorescence antibody labelling, flow cytometry 
and multiplex ELISA technology. 
hRP and hREC were successfully co-cultured, and the glucose and oxygen concentrations 
selected for the in vitro healthy and diabetic-like conditions were sufficient for cell viability and EC 
monolayer integrity, with evidence of an angiogenic response in diabetic-like conditions within the 
21 day timeframe. Angiopoietin-2 (Ang-2), vascular endothelial growth factor (VEGF), and platelet-
derived growth factor (PDGF) secretion were all increased, whilst hepatocyte growth factor 
(hHGF), tissue inhibitor for metalloproteinase-2 (TIMP-2) and interleukin-8 (IL-8) secretion were all 
reduced in the in vitro diabetic-like conditions. The secretion profile of co-cultures was different to 
mono-cultures, highlighting the importance of using co-culture models to collect data more 
reflective of the close relationship between hRP-hREC in vivo.  
Previous groups have developed useful co-culture models utilising non-human, immortalised or 
large vessel-sourced cells to explore changes to the vasculature during hypoxia and/or high 
glucose insult. In this study the use of human primary, retina-specific microvascular cells, mono- 
and co-cultured, collected over a longer culture period, has enabled detection of changes that may 
have been missed in previous models.  
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1. Introduction 1 
Diabetic retinopathy (DR) is a major microvascular complication of type 2 diabetes mellitus and 2 
leads to vision impairment in >10% of the type 2 diabetes population, equating to >45million people 3 
worldwide in 2015 (Yau et al., 2012). Vision-threatening DR is predicted to rise to >70 million 4 
people worldwide by 2040, resulting in major economic implications for health services and 5 
increased morbidity for people diagnosed with DR (Antonetti et al., 2004; Wild et al., 2004). Deeper 6 
understanding of the different stages of cellular change in the retinal capillary microenvironment 7 
could lead to novel, early-stage interventions, aimed at preventing vision loss.  8 
The current treatments of anti-vascular endothelial growth factor (VEGF) injections, which can be 9 
combined with laser therapy, are only offered at late-stage, once substantial damage has already 10 
occurred to the retinal capillaries (Medina et al., 2013). Development of early-stage therapies, 11 
which slow or prevent progression, are the ultimate goal. Unravelling the multifactorial aspects of 12 
the diabetic milieu, including chronic hyperglycaemia, metabolic dysregulation and ultimately tissue 13 
hypoxia, will aid in developing novel therapeutic targets.  14 
The retinal capillaries are composed of an inner layer of microvascular retinal endothelial cells 15 
(REC) with tight cell-cell contacts, forming the inner blood-retinal-barrier (BRB), and perivascular 16 
retinal pericytes (RP), which wrap around the endothelial cells (EC) providing structural and 17 
signalling support. This configuration enables the tightly regulated passage of substances from the 18 
blood, to the surrounding highly metabolically active tissue and vice versa. Loss of highly regulated 19 
EC-EC contacts, which in healthy conditions are formed by tight junctions (TJ), adherens junctions 20 
and gap junctions (GJ), is a major contributor to retinal capillary dysfunction and ultimately 21 
breakdown of the BRB. Structurally, basement membrane thickening and pericyte drop-out are 22 
early characteristics of DR, where disruption of both structural and cell signalling support from the 23 
RP is implicated in EC dysfunction and disease progression (Motiejunaite and Kazlauskas, 2008). 24 
However, the chronology of the alterations to cell signalling pathways, BRB breakdown, 25 
extracellular matrix (ECM) remodelling and cell death is not fully understood. 26 
VEGF and angiopoietin-2 (Ang-2) have major implications in DR progression, due to their 27 
involvement in driving the angiogenic switch from non-proliferative to the proliferative-stage (Stitt et 28 
al., 2016; Yao et al., 2007). The secretion profile of VEGF, Ang-2, and several other proteins 29 
involved in oxidative stress, angiogenesis and hyperglycaemia, is cell-type specific, therefore it is 30 
important to co-culture the cells comprising the microvasculature in vitro, in order to ascertain the 31 
most relevant cellular changes when modelling DR.  32 
Previously, large vessel-derived, mixed human/animal and immortalised cell co-culture models 33 
have been developed, to understand the complex EC:pericyte relationship in blood vessels (Kumar 34 
et al., 2011; Tarallo et al., 2012a; Walshe et al., 2011; Wisniewska- Kruk et al., 2012). Both 35 
hypoxia and hyperglycaemia are conditions encountered by the cells of the retinal 36 
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microvasculature at various stages throughout the progression of DR. To induce a diabetic-like 37 
phenotype in vitro, high glucose (33mM) and low oxygen (2%) can be used to accelerate the 38 
disease process, which often takes decades in humans. Although ECs in vivo are unlikely to 39 
experience simultaneous high glucose and low oxygen, metabolic memory is an important factor of 40 
the disease process (Kowluru et al., 2010), characterised by the imprinted effect of high glucose 41 
leading to a resistance in the halting of pathology even after restoration of glycaemic control. Using 42 
high glucose aims to induce and maintain the diabetic-like hyperglycaemic phenotype over time in 43 
vitro, whilst hypoxia aims to induce the oxidative stress ECs may encounter as blood vessel 44 
integrity begins to fail in the retinal microvasculature. The current study sought to develop a 45 
human, microvascular, in vitro co-culture model using commercially available human RP (hRP) and 46 
human REC (hREC). This is a novel, species and tissue-specific, reproducible co-culture model 47 
that can be used to study cellular changes, importantly over an extended period of time, as well as 48 
providing a potential tool to test novel DR-targeted therapies in vitro.   49 
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2. Materials and Methods 50 
2.1 Cell culture  51 
hREC (Cell Systems, Kirkland, WA, USA, ACBRI 181V) were used in experiments up to P10, 52 
cultured in PromoCell MV medium (PromoCell, Heidelberg, Germany) containing 5% foetal bovine 53 
serum (FBS), further supplemented with heat inactivated FBS (Labtech, East Sussex, UK) to final 54 
concentration of 10%. hREC were sub-cultured using 1X Trypsin-EDTA (Sigma, Dorset, UK) at 55 
~90% confluence. hRP (Cell Systems, ACBRI 183V) were used in experiments up to P10, cultured 56 
in DMEM (Life Technologies, Warrington, UK) supplemented with 1mM sodium pyruvate (Life 57 
Technologies), physiological (5.5mM) [D+] glucose (Life Technologies) and 10% FBS. hRP were 58 
sub-cultured at 70-80% confluence using 1X Trypsin-EDTA. To maintain cells with a 59 
physiologically healthy phenotype, cells were cultured in 20% oxygen and 5.5mM glucose. High 60 
glucose (33mM) was added to create a hyperglycaemic environment, in order to induce a diabetic-61 
like phenotype in vitro. Hypoxic (2% oxygen) insult was used simultaneously to induce an oxidative 62 
stress response in the hREC and hRP, which may be encountered by the cells comprising the 63 
retinal microvasculature as vessels regress or become unstable as DR progresses. 64 
2.2 Immunocytochemical staining  65 
Cells were fixed for 9 mins using 10% neutral buffered formalin (Sigma), at room temperature (RT). 66 
Cells were permeabilised using 0.5% Triton-X (Sigma) for 4 mins. Cells were blocked using 5% 67 
normal goat serum (Sigma) for 1 hour (H), at RT. Primary antibodies, (Table 1) were incubated 68 
overnight at 4°C. Secondary antibodies (Thermofisher, Waltham, MA, USA) were added at 5µg/ml 69 
for 45 mins at RT; goat anti-rabbit-488 and goat anti-mouse-594. For filamentous actin (F-actin) 70 
labelling, phalloidin-647 (Thermofisher) was used at 0.22µM and added with the secondary 71 
antibodies. Cells were washed in 0.1% Tween-20, then incubated with 300nM 4′,6-diamidino-2-72 
phenylindole (DAPI; Life Technologies) for 20 mins. After a final wash with ddH₂O, hardset 73 
mounting media (Agilent, Cheshire, UK) and a cover slip were added. 74 
2.3 Flow cytometry  75 
1x105 cells/tube were re-suspended in 100µl FACS buffer (dPBS +1% FBS). Fluorescent 76 
conjugated antibodies were added at 5µl/tube, or 6µl/tube for anti-CD34 (Table 2). Antibodies were 77 
incubated with cells at 4°C for 30 mins then washed in FACS buffer, supernatant removed and the 78 
cell pellet resuspended in 300µl fresh FACS buffer. Flow cytometry was performed using a BD 79 
Accuri-6 machine and Accuri-C6 software. Flow parameters were 1x104 events, on slow fluidics. 80 
Un-labelled cells were used to exclude dead cells/debris, and all samples were reported as % 81 
positivity vs corresponding conjugated IgG control; fluorescein isothiocyanate, phycoerythrin and 82 
allophycocyanin.  83 
2.4  Metabolic activity  84 
7 
 
Metabolic activity was measured using resazurin sodium salt (Sigma). A filtered PBS-resazurin 85 
solution at 0.01mg/ml with serum-free culture medium was incubated with cells at 37°C for 2H. 86 
Resazurin-media was transferred to black 96 well-plates (w/p) (Greiner Bio-One GmbH, 87 
Kremsmünster, Austria) and analysed using a FLUOstar Optima plate reader (BMG Labtech, 88 
Buckinghamshire, UK) with BMG Lab Tech (Optima, 2.20) software, at excitation 560nm and 89 
emission 590nm. Results were analysed using Optima Data Analysis MARS software. 90 
2.5 Co-culture model 91 
24 w/p hanging polyethylene terephthalate (PET) transwell membranes with 1µm pores (Merck, 92 
Darmstadt, Germany) were used untreated to seed mono- or co-cultures (Fig. 1A). To mimic the 93 
ratio of EC:pericyte coverage in the retina, cells were seeded 1:1 in co-culture. The experimental 94 
timescale is outlined in Figure 1B. 2x104 hRP were seeded on the underside of the transwell 95 
inserts, in 50µl of complete DMEM with 10% FBS, for 1H at 37°C. Transwells were reverted and 96 
placed into a 24 w/p with 900µl of MV medium containing 10% FBS/well. hREC were seeded at 97 
2x104 cells/insert in 200µl MV containing 10% FBS on the apical surface and plates were 98 
incubated overnight. For mono-cultures, only 1 cell-type was added (either hRP on the underside 99 
or hREC on the apical side). After 24H, inserts were transferred to a new 24 w/p and MV medium 100 
was reduced to 5% FBS. 72H after seeding, inserts were cultured in either physiological healthy 101 
conditions (20% oxygen + 5.5mM glucose) or 2% oxygen and 33mM glucose, for diabetic-like 102 
conditions. Cells were cultured for 21 days with media changed every 3-4 days. 103 
2.6 Human angiogenesis multiplex array  104 
The Q-Plex Human Angiogenesis Array (Quansys, Logan, UT, USA) uses multiplex technology to 105 
measure 9 secreted angiogenic proteins of interest: Ang-2, fibroblast growth factor (FGF), 106 
hepatocyte growth factor (hHGF), interleukin-8 (IL-8), platelet-derived growth factor-BB (PDGF-107 
BB), tissue inhibitor for metalloproteinase-1 and -2 (TIMP-1/-2), tissue necrosis factor-α (TNFα) 108 
and VEGF. 100µl of media was collected from the apical, and 100µl from the outer compartments 109 
at 7 time points (Day 0, 3, 7, 10, 14, 17, 21), and stored immediately at -80°C. The assay was 110 
performed according to manufacturer’s instructions. An 8-point calibration curve was prepared 111 
using the calibrator and the human sample diluent, for each plate. Samples were diluted 1:4 and 112 
loaded on to the Q-Plex Array 96-w/p. The Q-Plex TM Imager LS and Q-View Imager Pro Software 113 
were used for imaging and analysis. Exposure time was 270 seconds. Pericytes from a male donor 114 
of unspecified age were used for multiplex run 1, whilst pericytes from a female donor aged 55 115 
were used for runs 2 and 3, as supplied for CellSystems. hREC from the same female donor were 116 
used throughout. 117 
2.7 Microscopy  118 
The Nikon DIAPHOT with Top View 3.7 software, and the AxioVert A1 with ZEN Blue 2.3 software 119 
were used to capture phase contrast images. The Nikon E-TI, with NIS Elements AR 4.51.01 120 
software was used for cell counts. The Zeiss Confocal M800 with ZEN Blue 2.3 software was used 121 
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for imaging cells on glass slides and PET membranes. When imaging co-cultures, PET 122 
membranes were removed from their frames and transferred to glass slides. 123 
2.8 Statistical analysis 124 
Statistical analyses were performed using GraphPad Prism 8 software. Significance level of p<0.05 125 
was set for all experiments. Data were reported as mean, with standard deviation (SD). ANOVA or 126 
non-parametric testing were used for multiple comparisons and T-tests were used for comparisons 127 























3. Results 149 
3.1 hREC and hRP maintained their phenotype in vitro within the 21 day experimental 150 
timeframe 151 
A limitation of using human primary cells in vitro is their tendency to de-differentiate. hRP 152 
maintained their morphology of a large, irregular-shape, with cytoplasmic projections, and did not 153 
transition in vitro from P3-P10 (Fig. 2A). hREC retained a cuboidal, uniform size and shape, and 154 
formed a monolayer when confluent (Fig. 2B). hRP number increased over time (Fig. 2C), whereas 155 
hREC decreased in number from day 7-21 (Fig. 2D). 87.5% of hRP expressed CD146, indicating a 156 
heterogeneous population, concomitant with their pluripotent nature (Fig. 2E). hREC were CD34 157 
negative and CD31 positive, which is endothelial specific and present at the border of cell 158 
membranes, suggesting hREC retained a strong EC phenotype (Fig. 2F). Both hREC and hRP 159 
were CD14 and CD45 negative, distinguishing them from hematopoietic cells. hRP expressed 160 
antigens commonly used to confirm pericyte phenotype in culture; PDGFR-β, neuron-glial antigen 161 
2 (NG2) and CD90 (Fig. 2G), and exhibited +/- expression for alpha-smooth muscle actin (α-SMA). 162 
hREC expressed a number of key endothelial-specific proteins including vWF, localised to storage 163 
vesicles (Weibel-Palade bodies) (Fig. 2H). Positive expression of ZO-1 confirmed TJ formation and 164 
VE-Cad confirmed adherens junction formation. 165 
3.2 Both cell-types were viable in sustained hyperglycaemia and hypoxia  166 
Validation of long-term, high glucose and low oxygen conditions was required to induce a diabetic-167 
like phenotype in vitro, whilst aiming to maintain cell viability. hREC and hRP were initially cultured 168 
in 5% oxygen to induce a hypoxic response (Fig. S1, Fig. S2). Ang-2 appeared activated in hREC 169 
cultured in 5% oxygen (Fig. S1), and SOD-2 appeared activated in hRP cultured in 5% oxygen 170 
(Fig. S2). However, oxygen levels were further reduced to 2% after determining only minimal 171 
differences compared to 20% oxygen, in both 5.5mM and 33mM glucose conditions. By day 21, 172 
the metabolic activity of hRP cultured in 20% oxygen and 30mM glucose was significantly higher 173 
than hRP cultured in 5.5mM glucose (Fig. 3A; p= 0.0434). There was, however, no significant 174 
difference in metabolic activity between hRP cultured in 35mM vs 5.5mM glucose, at day 21 in 175 
20% oxygen (p>0.999). Importantly, by day 21 in 20% oxygen, there were fewer hRP in 35mM 176 
compared to 5.5mM glucose conditions (p=0.0002), suggesting hyperglycaemia at 35mM caused 177 
higher metabolic activity/cell in the hRP. By day 21 in hypoxia (2% oxygen), hRP had significantly 178 
higher metabolic activity when cultured in 20mM, 25mM and 30mM glucose compared to those 179 
cultured in 5.5mM glucose (Fig. 3B; p=0.0456, p=0.0342, p=0.0018, respectively), whilst there was 180 
no metabolic difference between hRP cultured in 35mM vs 5.5mM glucose. There was however, 181 
significantly more hRP at day 21 in 2% oxygen and 35mM glucose, compared to 2% oxygen and 182 
5.5mM glucose (Fig. 3B; p<0.0001), suggesting a lower metabolic activity/cell in the 183 
hyperglycaemic-hypoxic conditions. hREC cultured in 20% oxygen with 10-30mM glucose all had 184 
significantly lower metabolic activity at day 21 compared to 5.5mM glucose (Fig. 3C; p=0.0011 185 
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10mM, p=0.0069 15mM, p=0.0048 20mM, p=0.0074 25mM and p=0.0018 30mM). But, there was 186 
no significant difference between hREC metabolic activity in 5.5mM vs 35mM in 20% oxygen at 187 
day 21. There was however, significantly more hREC at day 21 in 20% oxygen in 5.5mM vs 35mM 188 
glucose (Fig. 3C; p=0.0058). Taken together these data suggest hyperglycaemia at 35mM causes 189 
higher metabolic activity/cell for hREC cultured in 20% oxygen at day 21 compared to 5.5mM. In 190 
2% oxygen, there was no difference in hREC metabolic activity in 5.5mM- 35mM glucose and also 191 
no significant difference in cell number (Fig. 3D). There were no significant differences between 192 
5.5mM glucose and 29.5mM Mannitol + 5.5mM glucose conditions for all experiments by day 21, 193 
controlling for the potential confounding osmotic effects of increasing glucose. 194 
3.3 Hypoxic conditions caused re-arrangement of the F-actin cytoskeleton, increased 195 
Ang-2 expression and caused hREC hypertrophy 196 
Changes to the hREC monolayer were explored to understand the effect of diabetic-like conditions 197 
on microvascular EC behaviour. There was no difference in surface antigens expression when 198 
using flow cytometry to compare day 0, day 21 healthy and day 21 diabetic hREC cultured on TC-199 
plastic (Fig. 4A). For hREC mono-cultured on glass slides, ZO-1, VE-Cad and CD31 localised at 200 
cell-cell junctions in the four experimental oxygen/glucose conditions at day 21 (Fig. 4B). 201 
Cytoskeletal F-actin was arranged in thick stress-fibre-like bands at the borders of the hREC 202 
cultured in 2% oxygen, whereas in 20% oxygen the F-actin was dispersed in thin fibres throughout 203 
the cell. Connexin-43 (Cx43) was expressed at both the cell-cell junctions and in the perinuclear 204 
compartment of mono-cultured hREC. However, in 2% oxygen, Cx43 was predominantly at the 205 
cell-cell junctions, indicating an increase in GJ formation. Ang-2 expression in hREC was higher in 206 
low oxygen conditions. The cell area of hREC cultured in 2% oxygen +33mM glucose was larger 207 
than those cultured in 20% oxygen +5.5mM glucose (Fig. 4C; p=0.0006). There were also more 208 
very large cells in 2% oxygen, although the number of focal adhesions per cell was not influenced 209 
by oxygen/glucose conditions (Fig. 4D). 210 
3.4 hRP cultures were heterogeneous indicated by αSMA and CD146 expression 211 
Cell surface antigen expression and growth of hRP in response to healthy or diabetic-like 212 
conditions were investigated. hRP CD90 expression was retained throughout the 21 day culture 213 
period (Fig. 5A), confirming a pericyte phenotype was maintained. CD105 expression was 214 
significantly reduced by day 21 in healthy hRP compared to day 0 hRP (p=0.0483). CD146 215 
appeared reduced at day 21 in both healthy and diabetic conditions, however, due to the large 216 
variation of CD146 expression in day 0 hRP cultures this was not statistically significant. 217 
Irrespective of culture condition, cell density or passage number, only a proportion of hRP 218 
expressed αSMA (Fig. 5B). Cytoplasmic protrusions of αSMA-positive hRP were visible through 219 
the 1µm pores of the PET in mono-cultures (Fig. 5C), and in co-cultures, where hREC were co-220 
cultured with and without a tight monolayer apically (Fig. 5D and Fig. 5E, respectively), 221 
demonstrating physical cell-cell contacts between hREC and hRP. 222 
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3.5 Mono- and co-cultured hREC maintained a monolayer in both in healthy and diabetic 223 
conditions  224 
Confocal immunofluorescence (IF) analysis of cells on PET membranes at day 21 confirmed hREC 225 
and hRP viability, and antibody labelling was used to analyse the EC barrier and assess oxidative 226 
and angiogenic responses. The expression of junctional, angiogenic and oxidative stress proteins 227 
by hREC cultured on PET for earlier time points of 7 and 14 days is shown in Fig. S3. At day 21, 228 
mono-cultured hREC expressed VE-Cad and ZO-1 at cell-cell junctions, in both healthy and 229 
diabetic conditions, on PET (Fig. 6A). The Cx43 expression pattern appeared more punctate and 230 
dense, in peripheral clusters in the diabetic mono-culture compared to healthy, but overall was less 231 
distinct at the cell-cell border on PET, when compared to hREC cultured for 21 days on tissue 232 
culture (TC)-treated glass (Fig. 4B). F-actin arrangement was aligned in parallel fibres in healthy 233 
mono-cultured hREC, compared to a more disorganised arrangement in diabetic conditions. The 234 
distinct ‘actin-banding’ on the hREC periphery when cultured in 2% oxygen on TC-treated glass 235 
(Fig. 4B), was not present when hREC were cultured on PET (Fig. 6A). Some of the differences 236 
reported between hREC cultured on TC-treated glass and PET may be due to differences in 237 
substrate stiffness and therefore, cell-ECM interaction, or the practicalities of imaging cells on the 238 
PET membranes. Z-stack imaging provided confirmation that both cell-types were present on 239 
either side of the PET membranes in the co-culture model. ZO-1 and VE-Cad were present at cell-240 
cell borders of co-cultured hREC in both healthy and diabetic conditions, although their expression 241 
appeared more uniform in diabetic conditions (Fig. 6B). Cx43 expression was more defined at cell-242 
cell borders in diabetic co-cultured hREC, compared to healthy co-culture. Overall, the EC barrier 243 
appeared present in both mono- and co-culture conditions, and unexpectedly was present in 244 
diabetic conditions at day 21, subjected to continuous hyperglycaemic and hypoxic insult. HIF1α 245 
expression appeared more perinuclear in diabetic co-culture compared to healthy co-cultures at 246 
day 21 (Fig. 6B), although overall the HIF1α results were inconclusive when analysed via IF. F-247 
actin arrangement in healthy co-cultured hREC was not aligned in thick parallel fibres like it was in 248 
mono-cultured hREC on PET (Fig. 6A) and TC-treated glass (Fig. 4B), suggesting fewer stress 249 
fibres within the hREC when co-cultured with pericytes. 250 
3.6 Ang-2, VEGF and PDGF were significantly higher in diabetic conditions  251 
To confirm a diabetic-like phenotype, secretion of the growth factors Ang-2, VEGF and PDGF were 252 
assessed for hREC and hRP grown individually and as co-culture, using multiplex analysis. 253 
Micrographs of the mono- and co-cultured hREC and hRP confirm the presence of the cells on the 254 
PET inserts in healthy and diabetic conditions at days 7, 14 and 21 (Fig. S4). Ang-2 was not 255 
secreted by mono-cultured hRP at any time point (Fig. 7A). Ang-2 secreted by diabetic mono-256 
cultured hREC and diabetic co-culture was more than double that of healthy by day 7 (Fig. 7B,C, 257 
p=0.0001 and p=0.0002). From days 7-21, Ang-2 remained significantly higher in diabetic 258 
conditions for both mono-cultured hREC and co-cultures. Although Ang-2 was not secreted by 259 
hRP, the presence of hRP in co-culture caused a 25.6% increase in secretion of Ang-2 in healthy 260 
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co-cultures, and 13.9% increase in diabetic co-cultures (Fig. 7C), compared to mono-cultured 261 
hREC at day 21 (Fig. 7B). VEGF was only secreted by hRP (Fig. 7D, E). VEGF was significantly 262 
higher in diabetic hRP vs healthy, at day 3 (p=0.0055), 7 (p=0.0093), 14 (p=0.0199) and 21 263 
(p=0.0019) (Fig. 7D). From day 3-17, diabetic VEGF levels were more than double those in healthy 264 
conditions, and by day 21, were 3 times higher in diabetic hRP (p=0.0019). VEGF levels in co-265 
culture were very low, suggesting the presence of hREC caused a reduction of VEGF secretion by 266 
the hRP (Fig. 7F). Similar to Ang-2, PDGF was secreted at very low/negligible levels by hRP (Fig. 267 
7G). By day 21, PDGF was 2.3-fold higher in diabetic hREC compared to healthy (Fig. 7H; 268 
p=0.0008) and 4.4-fold higher in diabetic co-culture vs healthy (Fig. 7I; p=0.0062). PDGF only 269 
reached significantly higher levels in diabetic mono-cultured hREC compared to healthy conditions 270 
at day 17 onwards (p=0.0158). Although hRP only secreted very low levels of PDGF, in co-culture 271 
the levels of PDGF in diabetic conditions exceeded what would be an additive effect of hREC and 272 
hRP alone, suggesting in diabetic but not healthy co-culture, higher levels of PDGF were secreted 273 
in the presence of hRP. These data support the strength of using long-term co-cultures to explore 274 
cellular changes when modelling DR.  275 
3.7 hHGF, TIMP-2 and IL-8 were significantly reduced in diabetic conditions  276 
A panel of proteins including hHGF, TIMP-2 and IL-8 were analysed to determine if the 277 
experimental diabetic conditions of the model were sufficient to induce differences to the secretion 278 
profile of hREC and hRP, and also assess if there was any paracrine effects when the cells were 279 
co-cultured. hHGF was secreted by mono-cultured hRP (Fig.7J), but was not secreted by mono-280 
cultured hREC at any time point (Fig. K). hHGF secretion was significantly lower in diabetic 281 
conditions from day 7 in mono-cultured hRP (Fig. 7J; p=0.0146) and co-culture (Fig. 7L; p=0.012), 282 
and remained significantly reduced in diabetic co-culture at day 21 (p=0.0303). Levels of hHGF in 283 
healthy and diabetic co-culture were lower than secretion levels by mono-cultured hRP at all time 284 
points, suggesting the presence of hREC in the co-culture caused a reduction in the overall 285 
secretion levels of hHGF. TIMP-2 was secreted by mono-cultured hRP (Fig.7M) and mono-cultured 286 
hREC (Fig.7N). TIMP-2 secretion was significantly reduced in diabetic conditions for mono- and 287 
co-culture models. This reduction was significant by day 14 in mono-cultured hRP (Fig.7M; 288 
p=0.0011), by day 10 in mono-cultured hREC (Fig. 7N; p=0.0451) and day 7 in the co-culture (Fig. 289 
7O; p=0.0165). At day 21, diabetic mono-cultured hREC secreted significantly less TIMP-2 (Fig. 290 
7N; p=0.0026), as did the diabetic co-culture, compared to healthy (Fig. 7O; p=0.0231). Overall 291 
TIMP-2 levels were highest in healthy co-culture at day 21, and this appears to be an additive 292 
effect of both hREC and hRP secreting TIMP-2. Although hHGF levels remained relatively 293 
consistent over time (Fig. 7J-L), IL-8 and TIMP-2 secretion increased in both healthy and diabetic 294 
conditions over time (Fig. 7M-R). Both mono-cultured hRP and hREC secreted IL-8 (Fig. 7P,Q) 295 
and it appeared that the levels of IL-8 in co-culture may be additive (Fig. 7R). Diabetic conditions 296 
caused a significant reduction in IL-8 by mono-cultured hRP at day 14 (Fig. 7P; p=0.0499), and 297 
although there was a trend for reduced IL-8 in diabetic mono-cultured hREC and the co-culture, the 298 
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reduction was not significant. The large standard deviation across several of the proteins analysed 299 
may be in part due to a different hRP donor being used in run 1. Data from all 3 repeats indicate a 300 
similar trend, with varying magnitude, for mono-cultured hRP and hREC (Fig. S5), and the co-301 
culture (Fig. S6), in healthy and diabetic-like conditions over time. Overall, the angiogenic protein 302 
release profiles highlight that hREC and hRP secreted different proteins, and that one cell-type can 303 
























4. Discussion 326 
The aim of this study was to develop a human primary, retina-specific, microvascular co-culture 327 
model to provide an in vitro environment to study cellular changes, disease progression and future 328 
cellular or pharmacological intervention for conditions such as DR. To induce a diabetic-like 329 
phenotype in vitro, simultaneous hyperglycaemia and hypoxia culture conditions were used. The 330 
key findings of this study were; (1) Human primary hREC and hRP maintained their phenotype and 331 
could be cultured together in vitro, (2) high glucose and low oxygen (in vitro diabetic-like) 332 
conditions caused an angiogenic response, (3) when hREC and hRP were co-cultured, their 333 
angiogenic response was different to mono-cultured cells, and (4) the extended 21 day timescale 334 
for experiments was important, as some changes in angiogenic response proteins were only 335 
observed at later time points.  336 
An in vitro model should mimic the in vivo situation as closely as possible, while recognising it may 337 
have limitations. Co-culturing primary, tissue-specific cells whilst ensuring that they retain their 338 
phenotype over time is one option for producing a simplified, reproducible in vitro model to study 339 
DR. Human primary vascular ECs from various organs/tissues, including the retina, are 340 
commercially available and ECs isolated from different organs are reported to behave differently 341 
(Craig et al., 1998). In addition, it has been shown that ECs sourced from larger vessels differ to 342 
those from microvasculature (Browning et al., 2012; Solomon et al., 2016). In this study we used 343 
human, primary, retinal microvascular cells (hREC) and demonstrated that they retained their cell-344 
specific markers up to 21 days in culture in both healthy and diabetic-like conditions, in contrast to 345 
other studies which used animal, immortalised or large vessel co-culture models (Kumar et al., 346 
2011; Tarallo et al., 2012a; Walshe et al., 2011; Wisniewska- Kruk et al., 2012). It is well known 347 
that hRP morphology enables them to wrap around the perivascular surface of ECs, sharing 348 
physical contact through a shared BM and communicating via paracrine signalling (Pfister et al., 349 
2013). This function has been observed in vitro when ECs and pericytes form structured tubules 350 
when cultured together in 3D gels (Stratman et al., 2016; Urich et al., 2013; Zouani et al., 2013). 351 
Some of the documented paracrine interactions of hREC and hRP include, PDGF-β, TGF-β and 352 
Ang-1/2 signalling, as well as adhesion plaque formation connecting ECs and pericytes, which 353 
enables transmission of contractile forces, affecting vessel stability (Tell et al., 2006). In the 354 
present study, cells were cultured on either side of transwell inserts and αSMA-positive hRP 355 
formed cytoplasmic protrusions through the 1µm pores in the PET membrane, allowing direct 356 
physical contact in some areas, which should be taken into account when analysing the data. A 357 
major focus of this study was the integrity of the endothelial monolayer, where ZO-1, VE-Cad and 358 
Cx43 expression at cell-cell junctions was used to confirm barrier homeostasis and effective cell-359 
cell communication. hREC formed a monolayer, with ZO-1 and VE-cad present at cell-cell borders 360 
in both mono- and co-cultures. Contrary to reports by other groups, hRP and hREC can be 361 
maintained in vitro (Berrone et al., 2009; Kashyap et al., 2013;), and cultured together, with no 362 
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clear indication of phenotypic switch, due to carefully adjusted culture conditions, rendering this 363 
model an improvement upon immortalised, animal, or large vessel co-culture options. 364 
Establishing the appropriate conditions of a disease model can be challenging, in particular, when 365 
modelling a chronic disease with multiple confounding co-morbidities. Throughout onset and 366 
progression of diabetes, capillary ECs and the perivascular pericytes progressively deteriorate due 367 
to hyperglycaemia. Disturbance to the capillary ECs, caused by EC and/or pericyte drop-out or 368 
capillary bed regression, can result in disrupted blood flow and eventually vessel occlusion, which 369 
in turn leads to ischemia, hypoxia and non-perfusion to the underlying retinal tissue. Our model 370 
aimed to represent vessels that have been subjected to high glucose insult due to diabetes, and 371 
also reduced oxygen, due to loss of BRB integrity and regression of the retinal capillary bed. The in 372 
vitro conditions were carefully developed to attempt to maintain a healthy phenotype, or induce a 373 
diabetic-like phenotype for the hREC and hRP, within a comparatively short timeframe relative to 374 
the progressive onset of diabetes in a patient. 1-2% oxygen has been used previously in studies 375 
investigating the effect of hypoxia on cells in vitro (Kumar et al., 2011; Liu et al., 2006; Oh et al., 376 
1999), therefore we chose 2% oxygen to maintain viability of the cells in the relatively long term 377 
culture period of the mono- and co-culture model in this study. Several groups have used 20-35mM 378 
[D]+ glucose to model diabetes in vitro, with 25mM being the most common (Amano et al., 2005; 379 
Giebel et al., 2005; Ho et al., 2000; Nyengaard et al., 2004; Piconi et al., 2004; Risso et al., 2001; 380 
Romeo et al., 2002; Trudeau et al., 2011). In a more recent tri-culture, human, retina-specific 381 
study, 40mM glucose was used to assess short term cellular response to hyperglycaemia (Fresta 382 
et al., 2020). We determined that glucose levels between 30-35mM had a metabolic effect on both 383 
hRP and hREC in vitro, which led to 33mM being used to model hyperglycaemia in this study, as 384 
others have done (Ho, et al., 2000).  385 
Hypoxia-induced oxidative stress plays a crucial role in DR progression (Li et al, 2012), and 386 
combined hyperglycaemia and low oxygen was expected to lead to hRP cell loss in vitro. But 387 
surprisingly, hRP thrived in low oxygen, high glucose conditions. However, in vitro hRP are more 388 
prone to apoptosis in fluctuating high glucose compared to sustained high glucose, which was 389 
used in the present study (Busik et al., 2008; Tarallo et al., 2012b). Oxygen levels in the retina 390 
have been reported to range from 1-5% (Ivanovic, 2009). Therefore, it may be due to fact that the 391 
hREC and hRP used in this study are primary cells and so are more robust against hypoxic insult 392 
than the immortalised or large vessel EC/pericytes that have previously been used in similar 393 
models. The unexpected trend of increased cell junction localisation of Cx43, ZO-1 and VE-Cad 394 
suggests the hREC monolayer barrier integrity was in fact enhanced by the low oxygen, high 395 
glucose environment, contrary to reports of disrupted EC integrity in the progression of diabetes 396 
(Singh et al., 2014). Various groups have suggested Cx43 expression is affected by diabetic 397 
culture conditions (Kuo et al., 2020; Roy et al., 2017). In the present study, Cx43 clustered 398 
specifically at hREC cell-cell junctions in low oxygen, compared to dispersed throughout the 399 
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cytoplasm with less specificity to the cell-cell junctions in healthy conditions. This indicates GJ 400 
activity was highly dynamic and was affected by oxidative and hyperglycaemic stress. It is possible 401 
that cells in sustained diabetic conditions have undergone an adaptive remodelling response, 402 
which may not have occurred if parameters such as fluctuating glucose, manipulation of the ECM, 403 
the addition of flow and of other perivascular cells, such as astrocytes, were included. However, 404 
those additions were beyond the scope of this particular study. 405 
Angiogenic signalling pathways are also heavily implicated in pericyte:EC homeostasis. Ang-2, 406 
VEGF, and PDGF secretion were all higher, whilst hHGF, TIMP-2 and IL-8 secretion were all 407 
reduced in diabetic-like compared to healthy conditions in this study. Alteration to the levels of 408 
these proteins will disrupt multiple signalling pathways involved in homeostasis, wound healing and 409 
vascular health. Intravitreal injection of anti-VEGF agents is the current gold standard for treating 410 
late stage DR, once PDR begins to cause vision problems (Medina et al., 2013). VEGF levels 411 
increase in the ocular fluid of patients with varying stages of DR, particularly during PDR 412 
(Baharivand et al., 2012). VEGF is a driver of pathological angiogenesis in ischemic and 413 
inflammatory diseases (Witmer et al., 2003), and in this study, was significantly higher in pericytes 414 
cultured in diabetic-like conditions, compared to healthy. Interestingly, very low/out of range levels 415 
of VEGF were detected in co-culture conditions, highlighting that the presence of hREC altered the 416 
secretion behaviour of hRP.  417 
A second major angiogenic driver is Ang-2, where Ang-2 outcompetes Ang-1 for Tie-2 receptor 418 
binding, resulting in destabilisation of the vasculature (Thurston et al., 2013). Ang-2 was 419 
upregulated in hREC mono-cultured in low oxygen for 21 days and secretion was significantly 420 
higher from day 7 in diabetic mono- and co-cultures compared to healthy conditions. High Ang-2 421 
levels have previously been reported in hREC cultured in diabetic conditions (Rangasamy et al., 422 
2011), and novel treatments for DR based on targeting Ang-2 are currently in early stage clinical 423 
trials (Stewart, 2017; Tell et al., 2006). It has been documented that brain microvascular ECs and 424 
rat brain pericytes have differential responses to glucose deprivation and hypoxia, with ECs 425 
displaying F-actin rearrangement within 24H exposure (Engelhardt et al., 2015), and similarly, in 426 
the present study there was F-actin rearrangement in hypoxic hREC, from dispersed, thin filaments 427 
in healthy conditions to increased numbers of thick peripheral stress fibres, a feature of many 428 
different types of hypoxic ECs in culture (Zieseniss, 2014). Human brain microvascular ECs 429 
cultured under hypoxia plus inflammatory activation using IL-1β, displayed F-actin rearrangement 430 
from a small number of thin, dispersed filaments in healthy conditions, to numerous, parallel thick 431 
fibres (Tang et al., 2020), similar to the stress-like fibres formed by hREC in the present study 432 
when cultured under hypoxic/high glucose conditions. This confirms the high glucose and low 433 
oxygen conditions activated signalling pathways involved in re-arrangement of the hREC 434 
cytoskeleton. We speculate that the difference in cell culture surface characteristics will effect cell-435 
ECM adhesion, which may also have affected F-actin alignment in hREC, accounting for the 436 
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differences observed between cells cultured on glass or PET. The presence of pericyte protrusions 437 
through the PET in co-culture may also affect hREC adhesion, resulting in F-actin re-arrangement. 438 
Interestingly, hREC also had a larger surface area by day 21 in hypoxic conditions, and this cell 439 
hypertrophy may be a cellular response to hypoxia; to increase oxygen diffusion across a larger 440 
surface area. Combined, increased VEGF and Ang-2, dynamic GJ activity, and actin cytoskeleton 441 
rearrangement indicate that the in vitro diabetic conditions initiated an angiogenic response.  442 
Traditional cell culture does not take into consideration the paracrine or structural effect of 443 
neighbouring cell-types. Therefore, to understand changes in the retinal microvasculature, where 444 
pericyte coverage is very high, developing a co-culture of 1:1 hRP and hREC, with shared 445 
basement membrane (BM) mimic, has provided valuable data on the cellular changes in diabetes. 446 
Others have highlighted the influencing effect of growth factors released from neighbouring cells on 447 
EC behaviour (Dohgu et al., 2005; Gardner et al., 1997), hence underlining the benefit of using co-448 
culture models as opposed to traditional mono-cultures. Our results confirmed that the angiogenic 449 
secretion profile and EC barrier integrity differed between mono- and co-cultures. Re-arrangement 450 
of the F-actin cytoskeleton in the co-culture vs hREC mono-culture and the observation of reduced 451 
junction-specific ZO-1, VE-Cad and Cx43 in co-culture supports the hypothesis that long-term co-452 
culture affects hREC structure and monolayer integrity.  453 
Assessing the secretion profile of mono-cultured and co-cultured cells in either healthy or diabetic 454 
conditions enabled assessment of cellular changes due to diabetic-like insult, as well as paracrine 455 
effects of neighbouring cells simultaneously. TIMP-2 is important for maintaining ECM 456 
homeostasis, and in pathological conditions such as DR the TIMP:matrix metalloproteinase (MMP) 457 
ratio can affect capillary BM thickening at an early stage (Castruita-De la Rosa et al., 2017; Roy et 458 
al., 2010). Reduced TIMP-2 levels may result in increased MMP activity, leading to increased ECM 459 
remodelling, and disruption to normal cell function, adhesion, and cell:cell communication, 460 
mimicking an angiogenic switch. TIMP-2 was secreted by both hRP and hREC, and was reduced 461 
in diabetic conditions in mono- and co-cultures. Ang-2 levels in co-culture were overall higher than 462 
hREC mono-culture, in both healthy and diabetic conditions, suggesting hREC secreted more Ang-463 
2 in the presence of hRP. hRP in mono-culture did not secrete Ang-2 at all. In a mouse study, high 464 
glucose caused Ang-2 induced pericyte apoptosis via α3β1 integrin (Park et al., 2014), suggesting 465 
raised Ang-2 may be responsible for the early-drop out of pericytes, a common observation in 466 
diabetic retinae (Motiejunaite and Kazlauskas, 2008). Many studies using both animal and human 467 
retinae found Ang-2/Tie signalling was critical for pericyte survival and interaction with underlying 468 
EC, wherein increased Ang-2 leads to unstable pericyte:EC contact points (Bergers and Song, 469 
2005; Hammes et al., 2004). Considering hRP did not secrete Ang-2 at all, the co-culture model is 470 
vital to highlight the differential secretion profiles of hREC and hRP, the effect each has on one 471 
another and to truly understand changes occurring in the retinal microvasculature.  472 
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Similarly, hREC did not secrete hHGF and hRP did not secrete PDGF, although their presence 473 
appeared to alter the secretion profile when in co-culture. hHGF, or scatter factor, has been 474 
described as both an adipocytokine and a hepatokine (Balaban et al., 2006), which has a role in 475 
metabolic flux of glucose in various insulin-sensitive cells, with growing evidence suggesting hHGF 476 
plays a role in metabolic disorders such as type 2 diabetes (Oliveira et al., 2018). A comprehensive 477 
study comparing human patients at various stages of eye disease, found vitreous hHGF levels 478 
significantly increase depending on severity of retinopathy (Nishimura et al., 1999). In the present 479 
study, however, hHGF was lower in diabetic-like conditions at all time points. Also, hHGF was 480 
reduced in both healthy and diabetic co-cultures compared to mono-culture hRP, suggesting the 481 
presence of hREC reduced the overall hHGF secretion. This paracrine effect is of vital importance 482 
when aiming to model a disease where ECs and pericytes appear to significantly influence one-483 
another’s secretion profile. PDGF is an important growth factor for all phases of wound healing as 484 
well as a potent mitogen for mesenchymal cells (Goksen et al., 2017). In a study focused on 485 
diabetic nephropathy, urinary excretion rates of PDGF-BB were significantly increased congruent 486 
to urine albumin excretion (Wang et al., 2009). This implies PDGF-BB may play a role in the onset 487 
of diabetes, linked with early microvascular changes. In the present study, hRP secreted very low/ 488 
undetectable PDGF within the 21 day timeframe. However, secretion of PDGF was higher in 489 
diabetic co-culture compared to mono-cultured hREC, suggesting the presence of a second cell-490 
type (hRP) in the co-culture changes the secretion profile. These results imply hREC and hRP 491 
have paracrine effect on the angiogenic secretion profile of one another, within the experimental 492 
parameters. This emphasises the value of a simplified in vitro co-culture model for unravelling the 493 
fundamental cellular changes in DR and for testing novel therapeutic targets in the future. 494 
When attempting to fully understand the stages of cellular alterations in a progressive disease, the 495 
value of collecting data over multiple time points is irrefutable. Data analysis at 7 time points, over 496 
21 days, has provided insight into cell behaviour over time, compared to previously published co-497 
culture models which range in time scale from: 24h, 2, 3 and 8 days (Hayashi et al., 2004; Tarallo 498 
et al., 2012a; Wisniewska-Kruk et al., 2012). Ang-2, PDGF, TIMP-2 and IL-8 secretion all 499 
increased over time. In particular, PDGF was significantly higher in diabetic mono-cultured hREC 500 
and co-culture, but only from day 17 and 21 respectively. In contrast, VEGF data suggests a 501 
diabetic-like state was induced in hRP in a relatively short culture time. Collection of data at 502 
multiple time points, over a long-term culture period helps to understand the chronology of 503 
changing cell behaviour related to the progression of DR.  504 
5. Conclusions 505 
These data confirm successful long term culture of stringently characterised hREC and hRP, 506 
individually and in co-culture. Introducing carefully selected in vitro healthy and diabetic-like 507 
conditions enabled data collection at multiple time points over 21 days and differences in the 508 
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angiogenic secretion profile of healthy compared to diabetic cells suggested an angiogenic switch 509 
in the low oxygen, high glucose environment. Significant differences were also discovered in 510 
mono- vs co-cultures, highlighting the importance of studying the behaviour of hRP and hREC 511 
together, rather than in isolation. This in vitro co-culture model could help unravel cell signalling 512 
changes caused by diabetes, and offer a reproducible model to assess novel pharmaceutical 513 
interventions aimed at targeting early stage DR. 514 
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Table 1: Primary antibodies for immunofluorescence 748 
Antibody Supplier Working 
concentration 
anti-αSMA Abcam, Cambridge, UK, ab7817 5µg/ml 
anti-Thy-1/CD90 Abcam, ab23894 2µg/ml 
anti-HIF1α Abcam, ab199004 1µg/ml 
anti-VEGFR-2 Abcam, ab9530 5µg/ml 
anti-Ang-2 Abcam, ab153934 7.2µg/ml 
anti-Desmin Abcam, ab15200 1.45µg/ml 
anti-vWF Abcam, ab6994 21.5µg/ml 
anti-VE-Cad Abcam, ab33168 3.5µg/ml 
anti-CD31 Abcam, ab2836 0.6µg/ml 
anti-Cx43 Abcam, ab11370 3.5µg/ml 
anti-Paxillin Abcam, ab32084 1:200 
anti-PDGFR-β Santa Cruz Biotech, Dallas, TX, 
USA, sc-374573 
0.8µg/ml 
anti-ZO-1 Invitrogen, Waltham, MA, USA, 
61-7300 
2.5µg/ml 
anti-SOD-2 Fisher Scientific, Loughborough, 
UK, A21990 
5µg/ml 
anti-SOD-1 Merck, MABC684 1:200 
anti-NG2 Merck, ab5320 5µg/ml 
 749 
Table 2: Primary antibodies for flow cytometry 750 
Conjugated antibody Supplier Volume/test 
anti-IgG-1 kappa-FITC Fisher Scientific, 15104218 5µl/test 
anti-IgG-1 kappa-PE Fisher Scientific, 12611959 5µl/test 
anti-IgG-1 kappa-APC Fisher Scientific, 12642059 5µl/test 
anti-CD31-APC Fisher Scientific, 15577906 5µl/test 
anti-CD146-PE Fisher Scientific, 15546896 5µl/test 
anti-CD105-PE Fisher Scientific, 15576846 5µl/test 
anti-CD90-APC Fisher Scientific, 17090942 5µl/test 
anti-CD14-APC Fisher Scientific, 15517886 5µl/test 
anti-CD45-FITC Fisher Scientific, 15556406 5µl/test 





Figure Legends 753 
Figure 1. Schematic of the in vitro setup, seeding method and timescales for the mono/co-754 
culture models 755 
Three models were analysed (A): 2x104 hREC only on the apical side of the PET, 2x104 hRP only 756 
on the underside of the PET, and the co-culture where 2x104 hREC were seeded on the apical 757 
side and 2x104 hRP seeded on the underside of the PET transwell insert at a 1:1 ratio. The method 758 
for seeding the cells is illustrated in B. Cells were seeded onto inserts as shown and placed in a 24 759 
w/p. Incubation steps were at 5% CO2 in air and 37°. For hREC only and hRP mono-cultures, only 760 
one cell-type was added to the insert. Cells were cultured for 21 days. Media samples were 761 
collected at day 0, 3, 7, 10, 14, 17 and 21 for multiplex analysis. This figure was created with 762 
BioRender.com.  763 
Figure 2. Characterisation of hRP and hREC 764 
A and B: Light micrographs illustrating the morphology of hRP and hREC cultured individually on 765 
TC plastic at passages 3-10. C and D: Graphs illustrating the effect of seeding density and time on 766 
growth rate of hRP (C) and hREC (D) seeded at 5x103, 1x104, 2x104 and 4x104/well in 24w/ps for 767 
21 days. n=3. E and F: Representative light micrographs of the cells that were used for flow 768 
cytometry analysis of surface receptors expressed on hRP P6 (E) and hREC P7 (F), cultured in 769 
healthy conditions until confluent (3-5 days). Results were reported for 1x104 events, % positivity 770 
against each fluorophore isotype control. hRP were CD146, CD105 and CD90 positive whilst 771 
hREC were CD146, CD31 and CD105 positive. Black scale bars =200µm. G and H: 772 
Immunofluorescence antibody labelling of cell-specific antigens on hRP (G), which were Ang-2, 773 
Desmin, NG2, PDGFR-β, CD90 and F-actin positive, and hREC (H), which were CD31, VE-Cad, 774 
ZO-1, vWF, Cx43 and F-actin positive. Isotype controls for normal mouse and rabbit IgG were 775 
used as negative controls. Cells were cultured on TC-treated glass until confluent, and imaged 776 
using confocal microscopy at x40 oil magnification. White scale bars= 50µm. 777 
Figure 3. Glucose and oxygen analysis for long-term culture of hRP and hREC  778 
hRP (A,B) and hREC (C,D) P6 were seeded at 1x104cells/well on 48w/ps in MV +10% FBS or 779 
DMEM + 10% FBS, both at 5.5mM glucose. 24H after seeding, cells were transferred to either 780 
20% oxygen or 2% oxygen, FBS was reduced to 5% and glucose was adjusted to 0-35mM for 21 781 
days. Mannitol at 29.5mM + 5.5mM glucose was used as an osmotic control. Resazurin was added 782 
at 8 time points in serum-free medium, for 2H. Resazurin media was collected and analysed at 783 
excitation 560nm and emission 590nm for n=5/condition, repeated twice. Brown-Forsythe and 784 
Welch ANOVA with Dunnett’s T3 post-hoc correction was used to determine differences in 785 
metabolic activity in 0-35mM glucose and for flow data analysis. For cell number at day 21, DAPI 786 
nuclear staining was analysed from 5 fields of view across 5 wells/condition. Unpaired t-test with 787 
Welch’s correction was used to determine differences between cell counts in 20% or 2% oxygen + 788 
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0-35mM glucose at day 21. Data are reported as mean ± standard deviation. *p<0.05, ** p<0.01, 789 
***p<0.001. Scale bar =200µm. 790 
Figure 4. hREC surface antigen expression, barrier properties, angiogenic response and 791 
cell size in healthy vs diabetic conditions 792 
A: hREC P5-7 were cultured until confluent (day 0) or for 21 days in either healthy or diabetic 793 
conditions to determine any changes to cell surface antigen expression. Results are reported from 794 
1x104 events. The experiment was repeated three times, with one representative run shown here. 795 
Brown-Forsythe and Welch ANOVA with Dunnett’s T3 post-hoc correction was used to determine 796 
differences in surface antigen expression. Black scale bars= 200µm. B: Cells were cultured on TC-797 
treated glass for 21 days in 20% or 2% oxygen and 5.5mM or 33mM glucose, in MV +5% FBS. 798 
Expression of ZO-1, VE-Cad, CD31, Cx43 and Ang-2 was assessed. Cells were imaged using 799 
confocal microscopy at x40 oil magnification. White scale bars =50µm. C: cell size (µm2) from 5 800 
fields of view, across 5 wells/condition, in 3 independent experiments was measured using ImageJ 801 
software. Graphs illustrate each measured cell to highlight the spread of cell size in the hypoxic 802 
conditions. One-way ANOVA with Holm-Sidak correction was used to determine differences 803 
between cell size for each condition, n=3. D: Anti-Paxillin antibody was used to determine the 804 
number of focal adhesions/cell size (µm2) in 5 fields of view/well for each condition. *p<0.05, ** 805 
p<0.01, ***p<0.001.  806 
Figure 5. Dynamic expression of αSMA, CD146 and CD105 by hRP  807 
A: hRP P5-7 were cultured until confluent (day 0) or for 21 days in either healthy or diabetic 808 
conditions to determine any changes to cell surface antigen expression. Results are reported from 809 
1x104 events. The experiment was repeated three times, with one representative run shown here. 810 
Brown-Forsythe and Welch ANOVA with Dunnett’s T3 post-hoc correction was used to determine 811 
differences in surface antigen expression, n=3. There was significant reduction in CD105 at day 21 812 
in healthy conditions vs day 0 (99% ±0.1% vs 55.8% ±11.6%, p=0.0483). Due to large variability in 813 
CD146 expression, results were not statistically different. B: IF antibody labelling of αSMA on hRP 814 
P6 grown for 7 days in healthy conditions on TC-treated glass. Cytoplasmic protrusions from 815 
αSMA- positive hREC (green) grown on the underside of the PET appear orange in mono-culture 816 
(C), co-culture with a confluent hREC apically (D), or if hREC did not form a mono-layer apically 817 
(E). Cells were imaged using confocal microscopy at x40 or x63 oil magnification. Z-stack images 818 
were produced using volume view plugin on Image J. Scale bars=50µm. 819 
Figure 6. hREC barrier properties and F-Actin arrangement in mono- & co-culture 820 
A: hREC were cultured on the apical surface of PET transwell inserts for 21 days in healthy or 821 
diabetic conditions. B: hREC and hRP were co-cultured 1:1, with hRP on the underside and hREC 822 
on the apical side of PET transwell inserts. For seeding, treatment and timescale for the models, 823 
see Fig. 1b. Antibodies against ZO-1, VE-Cad and Cx43 were used to assess the barrier properties 824 
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of the hREC. Phalloidin was used to analyse F-actin arrangement in hREC. Using z-stacking 825 
technology and volume view plugin on ImageJ software, hRP were observed on the underside of 826 
the PET in the z-projection micrographs. All images were captured using confocal microscopy, x40 827 
oil magnification. Scale bars= 50µm. 828 
Figure 7. Protein secretion profiles of hREC and hRP in healthy vs diabetic conditions  829 
hREC and hRP were cultured on PET membranes at 1:1 ratio, as mono- or co-cultures, in healthy 830 
(blue) or diabetic (magenta) conditions, for 21 days. At seven time points media was collected and 831 
analysed for secreted Ang-2 (A-C), VEGF (D-F), PDGF (G-I), hHGF (J-L), TIMP-2 (M-O) and IL-8 832 
(P-R), using Quansys Human Angiogenesis Multiplex arrays, with Q-View software. All samples 833 
were analysed in technical duplicates, and triplicates for each condition. Results were corrected 834 
against a media sample with no cells. Data presented is three independent experiments (n=3), and 835 
mean with standard deviation. For VEGF, hHGF and PDGF two independent experiments were 836 
analysed due to samples in one repeat being under the lower limit of detection. Two-way ANOVA 837 
with Sidak’s multiple comparison post-hoc test, to account for repeated measures, was used to 838 
perform statistical analysis, using GraphPad Prism 8 software. * p<0.05, ** p<0.01 and *** 839 
p<0.001. 840 
Supplementary Figure 1: 841 
hREC P8 were cultured on TC-treated glass slides for 7 days in different O2 and glucose levels, to 842 
induce a diabetic-like phenotype in vitro. Light microscope images were captured at day 7 before 843 
fixing, using the Nikon DIAPHOT at x10 magnification. Black scale bars= 200µm. hREC were fixed 844 
at day 7 and labelled with antibodies against CD31 and ZO-1 to assess hREC monolayer integrity, 845 
Ang-2 to determine angiogenic response, vWF to confirm endothelial phenotype, and SOD-1 to 846 
assess oxidative stress response. Slides were imaged using the Zeiss M800 confocal microscope, 847 
at x40 oil or x63 magnification. White scale bars= 50µm. 848 
Supplementary Figure 2: 849 
hRP P7 were cultured on TC-treated glass slides for 7 days in different O2 and glucose levels, to 850 
induce a diabetic-like phenotype in vitro. Light microscope images were captured at day 7 before 851 
fixing, using the Nikon DIAPHOT at x10 magnification. Black scale bars= 200µm. hRP were fixed 852 
at day 7 and labelled with antibodies against NG2 and PDGFR-β to confirm pericyte phenotype, 853 
HIF1α to assess hypoxic response and SOD-1 and -2 to determine oxidative stress response. 854 
Slides were imaged using the Zeiss M800 confocal microscope, at x40 oil magnification. White 855 
scale bars= 50µm. 856 
Supplementary Figure 3: 857 
hREC were cultured on the apical surface of PET transwell inserts for 7 or 14 days in healthy or 858 
diabetic conditions. For seeding, treatment and timescale for the models, see Fig. 1b. Antibodies 859 
against ZO-1, VE-Cad and Cx43 were used to assess the barrier properties of the hREC. Nuclei 860 
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were visualised with DAPI (blue). All images were captured using the Z800 confocal microscope, 861 
x40 oil magnification. Scale bars= 50µm. 862 
Supplementary Figure 4: 863 
hREC at P6 and hRP at P7 were seeded as mono- or co-cultures on PET transwell inserts and 864 
cultured for 72H until confluent. Cells on inserts were then transferred to either healthy (20% 865 
oxygen + 5.5mM glucose) or diabetic (2% oxygen + 33mM glucose) conditions for up to 21 days, 866 
as described in Fig.1. Live cells were imaged using the AxioVert A1 at days 7, 14 and 21, to 867 
ensure both cell-types were viable in the experimental conditions. Additional images were also 868 
captured at day 0, 3, 10 and 17 to validate that cells were present during each sample collection 869 
for multiplex analysis (data not shown). Scale bars=200µm. 870 
Supplementary Figure 5: 871 
hRP (A) and hREC (B), P5 were cultured on PET membranes as mono-cultures, in healthy (blue) 872 
or diabetic (magenta) conditions, for 21 days. At seven time points media was collected and 873 
analysed for secreted Ang-2, VEGF, PDGF, hHGF, TIMP-2 and IL-8, and using Quansys Human 874 
Angiogenesis Multiplex arrays, with Q-View software. All samples were analysed in technical 875 
duplicates, and triplicates for each condition. Each experimental repeat is shown as runs 1-3, to 876 
highlight variation in magnitude but the similarity in trend in healthy vs diabetic-like conditions. 877 
Where graphs are excluded in run 1, protein levels were below the detectable limit. 878 
Supplementary Figure 6: 879 
hREC and hRP, P5 were cultured on PET membranes at 1:1 ratio as co-cultures, in healthy (blue) 880 
or diabetic (magenta) conditions, for 21 days. At seven time points media was collected and 881 
analysed for secreted Ang-2, PDGF, hHGF, TIMP-2 and IL-8using Quansys Human Angiogenesis 882 
Multiplex arrays, with Q-View software. All samples were analysed in technical duplicates, and 883 
triplicates for each condition. Each experimental repeat is shown as runs 1-3, to highlight variation 884 
in magnitude but the similarity in trend in healthy vs diabetic-like conditions. Where graphs are 885 
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